Physician profile
Donald E Mansell
NPI 1730117862
$1,461.32
in general payments reported to CMS, 2019-2025
11 companies · $397 in 2025
The $397 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $17.05 · 2021: $51.26 · 2022: $61.25 · 2023: $307 · 2024: $482 · 2025: $397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,172 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,172.35 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $339.12 | 2022-2025 | Entyvio, Eohilia |
| Boston Scientific Corporation | $322.19 | 2020-2024 | Axios, Exalt Model D, X-Tack Endoscopic Helix Tacking System |
| Abbvie INC. | $268.79 | 2022-2025 | |
| Cook Medical LLC | $202.45 | 2019-2024 | Hemospray |
| Gilead Sciences, INC. | $125.00 | 2023 | Vemlidy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.39 | 2019 | |
| Madrigal Pharmaceuticals | $41.78 | 2025 | Rezdiffra |
| Olympus America INC. | $38.63 | 2022-2023 | Evis Eus Endoscopic Ultrasound Center, Evis Exera II Ultrasound Gastrovideoscope |
| Pentax of America, INC. | $24.10 | 2023 | Aloka Arietta 850 |
| Organon LLC | $23.65 | 2023 | Renflexis, Hadlima |
| Vivus LLC | $21.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Mansell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.